PL3439672T3 - Stabilizowane rozpuszczalne białko f rsv przed fuzją do zastosowania w profilaktyce zakażenia rsv - Google Patents

Stabilizowane rozpuszczalne białko f rsv przed fuzją do zastosowania w profilaktyce zakażenia rsv

Info

Publication number
PL3439672T3
PL3439672T3 PL17715692T PL17715692T PL3439672T3 PL 3439672 T3 PL3439672 T3 PL 3439672T3 PL 17715692 T PL17715692 T PL 17715692T PL 17715692 T PL17715692 T PL 17715692T PL 3439672 T3 PL3439672 T3 PL 3439672T3
Authority
PL
Poland
Prior art keywords
rsv
prevention
soluble protein
before fusion
stabilized soluble
Prior art date
Application number
PL17715692T
Other languages
English (en)
Inventor
Anders KRARUP
Johannes Petrus Maria Langedijk
Original Assignee
Janssen Vaccines & Prevention B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention B.V. filed Critical Janssen Vaccines & Prevention B.V.
Publication of PL3439672T3 publication Critical patent/PL3439672T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
PL17715692T 2016-04-05 2017-04-04 Stabilizowane rozpuszczalne białko f rsv przed fuzją do zastosowania w profilaktyce zakażenia rsv PL3439672T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163810 2016-04-05
EP17715692.4A EP3439672B1 (en) 2016-04-05 2017-04-04 Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection
PCT/EP2017/057962 WO2017174568A1 (en) 2016-04-05 2017-04-04 Stabilized soluble pre-fusion rsv f proteins

Publications (1)

Publication Number Publication Date
PL3439672T3 true PL3439672T3 (pl) 2021-06-14

Family

ID=55752165

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17715692T PL3439672T3 (pl) 2016-04-05 2017-04-04 Stabilizowane rozpuszczalne białko f rsv przed fuzją do zastosowania w profilaktyce zakażenia rsv

Country Status (30)

Country Link
US (2) US11155583B2 (pl)
EP (2) EP3808374A1 (pl)
JP (2) JP7088841B2 (pl)
KR (2) KR102506895B1 (pl)
CN (2) CN116063551A (pl)
AU (2) AU2017248021B2 (pl)
BR (1) BR112018070013A2 (pl)
CA (1) CA3018941A1 (pl)
CL (1) CL2018002826A1 (pl)
CY (1) CY1124019T1 (pl)
DK (1) DK3439672T3 (pl)
EA (2) EA202191622A1 (pl)
ES (1) ES2858315T3 (pl)
HR (1) HRP20210113T1 (pl)
HU (1) HUE053027T2 (pl)
IL (2) IL291604B2 (pl)
LT (1) LT3439672T (pl)
MA (2) MA43763B1 (pl)
MD (1) MD3439672T2 (pl)
MX (2) MX2018012094A (pl)
MY (1) MY190320A (pl)
PE (1) PE20190420A1 (pl)
PH (2) PH12018501962B1 (pl)
PL (1) PL3439672T3 (pl)
PT (1) PT3439672T (pl)
RS (1) RS61456B1 (pl)
SG (1) SG11201807913XA (pl)
SI (1) SI3439672T1 (pl)
SM (1) SMT202100106T1 (pl)
WO (1) WO2017174568A1 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2988780T (pt) * 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
WO2015013551A1 (en) 2013-07-25 2015-01-29 Marshall Christopher Patrick Conformationally stabilized rsv pre-fusion f proteins
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
MX2018012094A (es) * 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
EP3606942B1 (en) 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN112088014B (zh) 2018-02-28 2026-03-24 华盛顿大学 自组装纳米结构疫苗
PE20211469A1 (es) 2018-11-13 2021-08-05 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
JP2023519740A (ja) 2020-04-02 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化型ワクチン組成物
EP4171627A1 (en) 2020-06-29 2023-05-03 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
US20240228548A9 (en) 2021-02-19 2024-07-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
WO2024074584A1 (en) * 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024093554A1 (zh) * 2022-11-04 2024-05-10 北京康乐卫士生物技术股份有限公司 针对rsv的重组亚单位疫苗及其应用
CN118725052A (zh) * 2023-03-31 2024-10-01 清华大学 具有稳定融合前构象的呼吸道合胞病毒f蛋白
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
WO2025193857A1 (en) * 2024-03-12 2025-09-18 Calder Biosciences Inc. Improved rsv vaccine compositions & methods

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5994108A (en) 1991-11-05 1999-11-30 Board Of Regents, The University Of Texas System Mutant TAR virus and transdominant tat mutants as pharmacological agents
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
KR100918187B1 (ko) 1998-02-17 2009-09-22 쉐링 코포레이션 바이러스를 포함하는 조성물 및 바이러스 제제의 농축방법
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ATE519854T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6281823B1 (en) 1999-09-21 2001-08-28 Agere Systems Guardian Corp. Direct digital synthesis using a sine weighted DAC
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
CA2415688A1 (en) 2000-05-08 2001-11-15 Anand Rao Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
US20030232018A1 (en) 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
CA2478508C (en) 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
EP1506287B1 (en) 2002-05-14 2007-04-25 Merck & Co., Inc. Methods of adenovirus purification
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20040106184A1 (en) 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
JP4814800B2 (ja) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー チンパンジーアデノウイルスワクチン担体
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
WO2008133663A2 (en) 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
WO2008154456A2 (en) 2007-06-06 2008-12-18 Nationwide Children's Hospital, Inc. Methods and compositions relating to viral fusion proteins
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
EP2257809B1 (en) 2008-02-29 2012-02-08 Tibotec Pharmaceuticals Method for identifying inhibitors against viruses that use a class i fusion protein
US8225289B2 (en) 2008-03-04 2012-07-17 Wind River Systems, Inc. Method and system for improved tool interaction with a target
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
ES2987238T3 (es) 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
CN101464897A (zh) 2009-01-12 2009-06-24 阿里巴巴集团控股有限公司 一种词匹配及信息查询方法及装置
HUE039908T2 (hu) 2009-02-02 2019-02-28 Glaxosmithkline Biologicals Sa Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
WO2011045381A1 (en) 2009-10-15 2011-04-21 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
MX2012004222A (es) 2009-10-15 2012-06-08 Crucell Holland Bv Metodo para purificacion de particulas de adenovirus.
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
CA2804760A1 (en) 2010-07-02 2012-01-05 Ensysce Biosciences, Inc. Single-walled carbon nanotube/sirna complexes and methods related thereto
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US8317672B2 (en) 2010-11-19 2012-11-27 Kensey Nash Corporation Centrifuge method and apparatus
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
SG10201602434UA (en) * 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5845376B2 (ja) 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Rsvに対するワクチン
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
JP6210998B2 (ja) 2012-11-15 2017-10-11 一般財団法人化学及血清療法研究所 ベクターワクチンおよび生ワクチンの併用による感染症の予防方法
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9060975B2 (en) * 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
CN105189756B (zh) 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
CA2904758A1 (en) 2013-03-14 2014-09-25 Peroxyium, Inc., Delaware C Corp. Method of enhancing the biodistribution and tissue targeting properties of therapeutic ceo2 particles via nano-encapsulation and coating
US9856313B2 (en) * 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
WO2014170258A1 (en) 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g proteins
AU2014255864B2 (en) 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
PT2988780T (pt) * 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
WO2015013551A1 (en) 2013-07-25 2015-01-29 Marshall Christopher Patrick Conformationally stabilized rsv pre-fusion f proteins
CN111514314A (zh) 2013-09-19 2020-08-11 扬森疫苗与预防公司 改进的腺病毒配制品
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2016040556A1 (en) 2014-09-12 2016-03-17 Rsv Corporation Virosomes containing respiratory syncytial virus strain line 19 fusion protein and uses thereof
JP6350376B2 (ja) 2015-04-23 2018-07-04 住友金属鉱山株式会社 非水系電解質二次電池用正極活物質及びその製造方法、並びにその正極活物質を用いた非水系電解質二次電池
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
SG11201803581VA (en) 2015-10-29 2018-05-30 Univ Emory Chimeric RSV, Immunogenic Compositions, and Methods of Use
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
CN115960263A (zh) 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
MX2018012094A (es) * 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
US10522129B2 (en) 2016-10-06 2019-12-31 Gopro, Inc. Active acoustic and vibration noise canceling in waterproof camera
KR102771459B1 (ko) 2016-11-18 2025-02-25 삼성전자주식회사 복합양극활물질, 이를 채용한 양극과 리튬전지 및 그 제조방법
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
PE20211469A1 (es) 2018-11-13 2021-08-05 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
AU2020263900B2 (en) 2019-04-25 2026-04-16 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
KR20220008875A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 계절성 인플루엔자 백신과 아데노바이러스 기반 호흡기 세포융합 바이러스 백신의 공동투여
US20220193219A1 (en) 2019-05-15 2022-06-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
JP2023519740A (ja) 2020-04-02 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化型ワクチン組成物
EP4171627A1 (en) 2020-06-29 2023-05-03 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection

Also Published As

Publication number Publication date
MX2018012094A (es) 2019-01-10
JP7362819B2 (ja) 2023-10-17
MA52910A (fr) 2021-04-21
EP3808374A1 (en) 2021-04-21
EA202191622A1 (ru) 2022-01-31
PH12022552125A1 (en) 2023-04-12
AU2021209185A1 (en) 2021-08-19
CL2018002826A1 (es) 2018-11-16
US20220089652A1 (en) 2022-03-24
LT3439672T (lt) 2021-01-25
WO2017174568A1 (en) 2017-10-12
IL291604B2 (en) 2024-02-01
IL262108B2 (en) 2023-04-01
PH12018501962A1 (en) 2019-06-24
MY190320A (en) 2022-04-13
EA039095B1 (ru) 2021-12-03
MX2022015257A (es) 2023-01-11
SG11201807913XA (en) 2018-10-30
PH12018501962B1 (en) 2023-09-08
AU2017248021B2 (en) 2021-08-12
IL262108A (en) 2018-11-29
CN109069616A (zh) 2018-12-21
SI3439672T1 (sl) 2021-02-26
EA201892251A1 (ru) 2019-03-29
SMT202100106T1 (it) 2021-03-15
KR20220041966A (ko) 2022-04-01
BR112018070013A2 (pt) 2019-02-05
IL291604B1 (en) 2023-10-01
PE20190420A1 (es) 2019-03-19
EP3439672B1 (en) 2020-11-25
IL262108B (en) 2022-12-01
EP3439672A1 (en) 2019-02-13
MA43763B1 (fr) 2021-03-31
KR20180131584A (ko) 2018-12-10
HRP20210113T1 (hr) 2021-03-05
JP2019513377A (ja) 2019-05-30
JP7088841B2 (ja) 2022-06-21
KR102506895B1 (ko) 2023-03-08
MD3439672T2 (ro) 2021-04-30
DK3439672T3 (da) 2021-02-15
IL291604A (en) 2022-05-01
AU2021209185B2 (en) 2023-06-01
RS61456B1 (sr) 2021-03-31
US11155583B2 (en) 2021-10-26
CN116063551A (zh) 2023-05-05
PT3439672T (pt) 2021-02-24
HUE053027T2 (hu) 2021-06-28
CA3018941A1 (en) 2017-10-12
AU2017248021A1 (en) 2018-10-04
US20190119330A1 (en) 2019-04-25
CY1124019T1 (el) 2022-05-27
JP2022101561A (ja) 2022-07-06
US12234264B2 (en) 2025-02-25
MA43763A (fr) 2019-02-13
ES2858315T3 (es) 2021-09-30

Similar Documents

Publication Publication Date Title
HUE053027T2 (hu) Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra
HRP20251569T1 (hr) Mutanti proteina rsv f
EP3497086A4 (en) AMINOPYRIMIDINE SSAO INHIBITORS
IL269490B (en) Surface treatment methods and compositions therefor
SI3785717T1 (sl) Postopki za zdravljenje okužb s Coronaviridae
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
DK3464331T3 (da) Stabiliserede præfusions-rsv f-proteiner
DK3474804T3 (da) Medicinsk forbinding
EP3378606A4 (en) AUXILIARY SET
EP3531991C0 (en) WHOLE BODY HYPERTHERMIA SYSTEM
HUE055762T2 (hu) Nyújtott hatású készítmények
DK3532067T3 (da) Liposomal formulering til anvendelse til behandling af cancer
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
EP3555092A4 (en) PROTEIN KINASE INHIBITORS
DK3538029T3 (da) Ledimplantat til vævsnydannelse på leddet
EP3431808A4 (en) BUFFER STOPPER
IL251345B (en) Compositions for use in the treatment of peri-implantitis
HUE056798T2 (hu) Imatinib stroke kezelésében való alkalmazásra
EP3429581A4 (en) ENALAPRIL FORMULATIONS
PL3338929T3 (pl) Płytka skrawająca
FI20165885A7 (fi) Ultraäänikiteytinlaite ja ultraäänikiteytinjärjestelmä
HUE056271T2 (hu) Candida fertõzések elleni készítmények
DK3380487T3 (da) Additivsystemer til anvendelse i proteinpegylering
EP3524240A4 (en) UREA DERIVATIVE
LT3290436T (lt) Fenilalanino neturintis baltymas, skirtas fenilketonurijos gydymui